Identify patients that may benefit from anthracycline in their CT regimen.
Identify patients that may benefit from anthracycline in their CT regimen.
Clinical evidence demonstrates that MammaPrint + BluePrint can guide chemotherapy selection in HR+/HER2- early stage breast cancer.
Neoadjuvant CT Selection Data
Patients with MammaPrint High 2 tumors (both Luminal B and Basal subtypes) are more likely to achieve a pCR in response to anthracycline-based neoadjuvant chemotherapy, compared to MammaPrint High 1 tumors.
(Audeh et al., Miami Breast 2024, #36)
Adjuvant CT Selection Data
Recent data demonstrate that MammaPrint High 2, BluePrint Luminal B, is predictive of benefit from AC-T therapy, with a higher 3-year RFS rate than with TC therapy, alone.
(O’Shaughnessy et al., ASCO 2024 #511)
Dive deeper into the data with our Medical team
Request Data Review / Additional Data:
